We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
Turnover
18.48%
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+35.46%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.1B
AUM Growth
+$3.24B
(+23%)
Cap. Flow
+$452M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
74.38%
Holding
100
New
9
Increased
23
Reduced
7
Closed
14
Avg Time Held
3.3
years
Top 10 Avg Time Held
4.6
years
Top 20 Avg Time Held
3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$135M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$92.2M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$81.4M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$60.9M |
| 5 |
Alkermes
ALKS
|
+$57.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merus
MRUS
|
+$54.1M |
| 2 |
Intellia Therapeutics
NTLA
|
+$47.4M |
| 3 |
Stoke Therapeutics
STOK
|
+$39M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$27.2M |
| 5 |
Vaxcyte
PCVX
|
+$23.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.61% |
| 2 | Miscellaneous | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
4D Molecular Therapeutics
FDMT
$680M
| $3.57M | 0.02% |
+475,737
| New | +$4.83M |
2025 Q4
0 quarters
|
|
77
Vir Biotechnology
VIR
$1.69B
| $3.27M | 0.02% |
542,539
| – | – |
2024 Q4
4 quarters
|
|
78
TScan Therapeutics
TCRX
$16.2M
| $2.78M | 0.02% |
2,784,792
| – | – |
2021 Q3
17 quarters
|
|
79
Sana Biotechnology
SANA
$686M
| $1.26M | 0.01% |
310,483
-1,720,466
| -85% | -$7.7M |
2023 Q1
11 quarters
|
|
80
Skye Bioscience
SKYE
$6.86M
| $1.09M | 0.01% |
181,330
| – | – |
2024 Q2
6 quarters
|
|
81
KALA BIO
KALA
$3.62M
| $1M | 0.01% |
36,081
+16,379
| +83% | +$733K |
2022 Q4
12 quarters
|
|
82
Aligos Therapeutics
ALGS
$31.5M
| $774K | ﹤0.01% |
83,055
| – | – |
2020 Q4
20 quarters
|
|
83
Tyra Biosciences
TYRA
$1.27B
| $279K | ﹤0.01% |
10,607
| – | – |
2023 Q4
8 quarters
|
|
84
Acrivon Therapeutics
ACRV
$71.6M
| $55K | ﹤0.01% |
22,809
| – | – |
2024 Q1
7 quarters
|
|
85
DELISTED
Surrozen Inc Warrant
SRZNW
| $16.7K | ﹤0.01% |
833,333
| – | – |
2021 Q3
17 quarters
|
|
86
DELISTED
Arcellx
ACLX
| – | – |
-166,825
| Closed | -$13.7M | – |
|
87
Agios Pharmaceuticals
AGIO
$1.89B
| – | – |
-189,866
| Closed | -$7.62M | – |
|
88
DELISTED
Akero Therapeutics
AKRO
| – | – |
-324,630
| Closed | -$15.4M | – |
|
89
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-227,272
| Closed | -$21.8M | – |
|
90
DELISTED
Generation Bio
GBIO
| – | – |
-194,493
| Closed | -$1.19M | – |
|
91
Heron Therapeutics
HRTX
$68.8M
| – | – |
-4,251,951
| Closed | -$5.36M | – |
|
|
92
DELISTED
Merus
MRUS
| – | – |
-574,377
| Closed | -$54.1M | – |
|
|
93
Intellia Therapeutics
NTLA
$1.54B
| – | – |
-2,746,674
| Closed | -$47.4M | – |
|
|
94
Vaxcyte
PCVX
$9.85B
| – | – |
-640,885
| Closed | -$23.1M | – |
|
|
RNAM
95
DELISTED
Avidity Biosciences
RNAM
| – | – |
-625,000
| Closed | -$27.2M | – |
|
96
Viking Therapeutics
VKTX
$3.21B
| – | – |
-366,083
| Closed | -$9.62M | – |
|
|
YARW
97
Yarrow Bioscience
YARW
$159M
| – | – |
-17,027
| Closed | -$285K | – |
|
98
MBX Biosciences
MBX
$2.42B
| – | – |
-277,777
| Closed | -$4.86M | – |
|
|
OPT
99
DELISTED
Opthea Limited American Depositary Shares
OPT
| – | – |
-2,087,320
| Closed | – | – |
|
Similar funds
SA
Baker Bros. Advisors's Q4 2025 Portfolio in Review
As of Q4 2025, Baker Bros. Advisors held 100 positions worth $17.1B, up 23% from $13.8B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Baker Bros. Advisors's Q4 2025 filing shows 9 new, 23 increased, 7 reduced and 14 closed positions. Its largest new stake was Terns Pharmaceuticals: 950,000 shares worth $38.4M. The largest sale was Merus, an estimated $54.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Baker Bros. Advisors's largest Q4 2025 buy was Terns Pharmaceuticals: 950,000 shares worth $38.4M.
- Baker Bros. Advisors added most to Kymera Therapeutics in Q4 2025, an estimated $135M increase.
- Baker Bros. Advisors's biggest Q4 2025 reduction was Stoke Therapeutics, cutting an estimated $39M.
- Baker Bros. Advisors fully exited Merus in Q4 2025, selling an estimated $54.1M.
- Baker Bros. Advisors's ten largest holdings make up 74% of its $17.1B portfolio in Q4 2025.
- Baker Bros. Advisors opened 9 new positions and closed 14 in Q4 2025.
- Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $17.1B.
Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.